Background: Previous work has suggested that an increase in expression of cyclooxygenase-2, concomitant formation of E-type prostanoids, and in turn intracellular cAMP conveys macrophage resistance against apoptosis. Materials and Methods: We analyzed the effects of lipophilic cAMP analogs on nitric oxide (NO)-induced apoptosis in RAW 264.7 macrophages and human primary monocyte-derived macrophages. Parameters comprised DNA fragmentation (diphenylamine assay), annexin V staining of phosphatidylserine, caspase activity (quantitated by the cleavage of a fluorogenic caspase-3-like substrate Ac-DEVD-AMC), and mitochondrial
Introduction
Cyclooxygenase-2 (Cox-2), also known as prostaglandin (PG) H synthase, catalyzes the ratelimiting steps in the formation of prostaglandin endoperoxides (1) . Prostanoids function as extracellular or intracellular messengers (1, 2) , and blocking nitric oxide (NO)-synthase confers resistance to a cytotoxic response initiated by exogenously added NO donors (8) . Cox-2 expression was determined a necessary component in the signaling cascade leading to this protection by reducing resistance by the Cox-2-specific inhibitor and by Cox-2 antisense transfection (9) .
Overexpression of Cox-2 in several pathological conditions such as colon carcinoma or rheumatoid arthritis points to a causative role of Cox-2 in tumor initiation and/or promotion. Furthermore, in line, the chronic use of nonsteroidal anti-inflammatory drugs such as aspirin reduces the incidence of colon cancer (10) and use of anti-inflammatory drugs such as sulindac abrogate tumorigenesis in experimental murine models of colon cancer (1 1) . Often, tumor prostanoid synthesis is enhanced, and the growth of some established tumor cell lines is inhibited in vitro and in athymic mice by Cox-2 inhibitors. Cox-2 knockout experiments provide further evidence for the requirement of Cox-2 in the development of some cancers, e.g., colon cancer (12) (13) (14) (15) . One mechanism for tumor development under conditions of Cox-2 overexpression may stem from inhibition of apoptosis as shown in gastrointestinal epithelial cells (16) . However, the signal-transducing pathways that convey Cox-2-evoked cell protection and/or decrease apoptosis remain elusive. Since attenuated macrophage apoptosis may contribute to inflammatory conditions such as sepsis or atherosclerosis, it is pertinent to gain insights into underlying signaling mechanisms.
We sought to elucidate how lipophilic cAMP analogs decrease NO-elicited apoptosis. The aim of this study was to determine whether protective principles operate in both murine and human macrophages and to establish pro-apoptotic parameters relative to the interference evoked by a cAMP response. Our experiments suggest that cAMP-mediated gene activation in murine and human macrophages is the predominant underlying protective principle.
Materials and Methods
Materials Diphenylamine, bovine serum albumin (BSA), and LPS (E. coli serotype 0127:B8) were purchased from Sigma (Deisenhofen, Germany).
L-NG-nitroarginine methyl ester (L-NAME)
was from Alexis (Grunberg, Germany). Recombinant murine IFN-,y, 8-bromo-cAMP (8-Br-cAMP), and dibutyryl-cAMP (db-cAMP) were provided by Boehringer Mannheim (Mannheim, Germany). RPMI 1640, cell culture supplements, and fetal calf serum (FCS) were ordered from Biochrom (Berlin, Germany). N-acetyl-Asp-Glu-Val-7-amino-4-methylcoumarin (Ac-DEVD-AMC) was bought from Biomol (Hamburg, Germany), and spermine-NONOate (Sp-NO) was obtained from Bio-Trend (Koln, Germany). The p53-antibody (PAb248) was kindly provided by H. Stahl, Homburg/Saar, Germany. All other chemicals were of the highest grade of purity and are commercially available.
Cell Culture
The mouse monocyte/macrophage cell line RAW 264.7 was maintained in RPMI 1640 supplemented with 100 U/ml penicillin, 100 ,tg/ml streptomycin, and 10% heat-inactivated FCS (complete RPMI). All experiments were performed with complete RPMI. NO donors, 8-BrcAMP, and db-cAMP were dissolved in twicedistilled water. Appropriate vehicle controls were performed.
Monocyte Isolation and Culture Cells were isolated from 50 ml buffy coats (Blutbank Erlangen, Erlangen, Germany). Blood was diluted 1:2 with phosphate-buffered saline (PBS) and layered on a Ficoll-Isopaque-gradient (p = 1077 g/ml). The interphase containing peripheral blood mononuclear cells (PBMC) was obtained following centrifugation (800 X g, 20 min). Cells were recovered and washed twice in PBS, and monocytes were isolated using magnetic cell sorting (MACS) technology (Miltenyi Biotec, Bergisch Gladbach, Germany) as described by the supplier to deplete CD 14- (17, 18) . Cells were grown in Teflon bags (SSud-Laborbedarf GmbH, Gauting, Germany) in RPMI 1640 containing 10% heat-inactivated human antibody serum (Sigma) and antibiotics (100 U/ml penicillin, 100 ,ug/ml streptomycin). After 6 days of culture, monocytes acquired a macrophage-like phenotype (19) and were used for the experiments. Teflon bags were used to culture the monocyte/macrophage population to avoid adherence (20) .
Quantitation of DNA Fragmentation DNA fragmentation was measured by the diphenylamine assay as previously reported (21) . Briefly, following incubations, cells were scraped off the culture plates, resuspended in 250 ,ul 10 mM Tris, 1 mM EDTA, pH 8 .0 (TE buffer), and incubated with an additional volume of lysis buffer (5 mM Tris, 20 mM EDTA, pH 8.0, 0.5% Triton X-100) for 30 min at 4°C. After lysis, the intact chromatin (pellet) was separated from DNA fragments (supernatant) by centrifugation for 15 min at 13000 x g. Pellets were resuspended in 500 Al TE buffer and samples were precipitated by adding 500 Al 10% trichloroacetic acid at 4°C. Samples were pelleted at 1400 X g for 10 min and the supernatant was removed. After addition of 300 ,ul of 5% trichloroacetic acid, samples were boiled for 15 min. DNA contents were quantitated using the diphenylamine reagent (22 tion of db-cAMP reduced DNA degradation under these conditions (Fig. IA) .
We also noticed unaltered p53 accumulation as a result of GSNO exposure in samples that received db-cAMP beforehand (Fig. IB) In further experiments we extended the preexposure period with liphophilic cAMP analogs. Preincubation of macrophages for 15 hr with either 1 mM 8-Br-cAMP or 1 mM db-cAMP conferred resistance against 1 mM GSNO-induced DNA fragmentation. Cells with the addition of cAMP analogs showed around 5% DNA fragmentation compared to 25% of uninhibited controls ( Fig. 2A) . A similar degree of protection was achieved with the combination of Sp-NO/cAMP analogs. Sp-NO-elicited DNA fragmentation of 25% was drastically 7oduced to roughly 5 % by the liphophilic cAMP pretreatment. Prolonged preincubation of macrophages with cell-permeable cAMP derivatives blocked DNA fragmentation by 60% to 80%. Significant reduction was also obtained by LPS/IFN-y/NAME preactivation, an established protocol to promote Cox-2 expression and concomitant cAMP-elevating prostanoid formation (9, 33) . We then sought to correlate suppressed DNA fragmentation with the NO donor-elicited p53 response (Fig. 2B) . Western blot analysis revealed no or only minor expression of p53 in controls, but showed massive protein accumulation within a 4-hr treatment with 1 mM GSNO (Fig. 2B, lane 3) .
Addition of lipophilic cAMP analogs for 15 hr blocked GSNO-promoted p53 accumulation (Fig. 2B, lanes 5 and 6) , with db-cAMP or 8-BrcAMP being similarly effective. For comparison we found reduced p53 immunoreactivity following LPS/IFN-y/NAME prestimulation for 15 hr (Fig. 2B, lane 4) . We further verified these results by following caspase-3 activation. Thus, cells were pretreated with db-cAMP for 15 hr followed by the addition of 1 mM GSNO or 0.25 mM Sp-NO for 4 hr (Fig. 2C ). Under these conditions, NO-evoked caspase-3 activation was largely attenuated (80-90%) by db-cAMP (Fig. 2C) . We then followed cAMP-evoked protection by measuring the mitochondrial membrane potential (At) using DiOC6(3) (Fig. 2D) . Control macrophages exhibited a high AT, which was significantly lowered when 1 mM GSNO was added for 8 hr. Under the influence of GSNO, 26% of the cells showed a decrease in AT that was not evident when cells were preexposed to db-cAMP.
Additional experiments in RAW 264.7 macrophages revealed decreased cytochrome c relocation in response to 1 mM GSNO or 0.25 mM Sp-NO when cells were pretreated with dbcAMP (Fig. 3A) . A decreased expression of the anti-apoptotic protein BCl-XL that occurred after the addition of NO was absent when macrophages were exposed to db-cAMP beforehand (Fig. 3B) . cAMP 
Confers Resistance Against GSNO in Human Macrophages
To verify the efficiency of lipophilic cAMP analogs in primary macrophages, we isolated human monocytes, then differentiated them to macrophages. We analyzed the first set of examinations by annexin V staining (Fig. 4A) ; annexin binds to phosphatidylserine exposed on the outer leaflet of the plasma membrane of apoptotic cells. In controls we saw 1-2% annexin-positive cells. This proportion increased to 37% after 4 (Fig. 4B) . Accumulation of the tumor suppressor was hindered by cAMP pretreatment.
Exposure of human macrophages to GSNO resulted in caspase activation, which is another indicator of apoptosis. Prestimulation of human macrophages for 15 hr with db-cAMP attenuated NO-initiated caspase activation (Fig. 4C) . Furthermore, breakdown of AT that occurred in human macrophages as a result of GSNO application was decreased by the addition of db-cAMP (Fig. 4D) , and 3-5% of control cells showed a decrease in AT. Within 8 hr GSNO brought these values up to 26%, whereas db-cAMP attenuated NO-evoked AT breakdown. We conclude that preactivation of murine or human macrophages for an extended time with cAMP analogs inhibits NO-induced apoptosis.
The Role of Cox-2 in Macrophage Protection Apparently, in order to inhibit NO-induced apoptosis-i.e., DNA fragmentation, p53 accumulation, annexin V binding, caspase-3 activation, cytochrome c relocation, At breackdown, and down-regulation of BCl-XL-lipophilic cAMP analogs require a long preincubation period. The extended presence of cAMP that is needed to attenuate apoptosis suggests that protection is achieved by cAMP-mediated gene induction. Obviously, Cox-2 expression is not responsible for cAMP-induced protection, which is in contrast to LPS/IFN-,y/NAME prestimulation (9) . Although Cox-2 expression occurs after cAMP stimulation (data not shown), the Cox-2-specific inhibitor NS-398 (10 ,uM) left cAMP-evoked cell protection unaltered and only blocked LPS/IFNy/NAME-mediated protection (Fig. 5) . reversed protection in LPS/IFN-,y/NAME-prestimulated cells, thus allowing 25% DNA breakdown, which is comparable to GSNO-treated macrophages.
In contrast, the addition of NS-398 left cAMP-induced protection unaltered. Therefore, Cox-2 expression is a prerequisite for LPS/IFNy/NAME-but not cAMP-evoked resistance against NO-mediated apoptosis. To prove the hypothesis that gene induction as a result of cAMP action is responsible for cellular protection, we used a decoy oligonucleotide approach to reverse protection.
Control GSNO db-cAMP/
GSNO0
Annexin V-FITC (log) kDa (38) . For macrophages we established p53 to be at least partly involved in conveying the apoptotic initiating activity of nitric oxide (39) .
Previously, we demonstrated that macrophage prestimulation with LPS/IFN-'y/NMMA protected macrophages against NO-mediated apoptosis by promoting Cox-2 expression; a 15 hr preincubation period was required to inhibit apoptosis (9) . Expression of Cox-2 in the sequence of events leading to colorectal cancer has been determined and genetic evidence links Cox-2 to tumorigenesis (16, 40) . The use of Cox-2-selective inhibitors as therapeutic agents for colorectal polyposis and cancer joins Cox-derived metabolites and deregulation of apoptosis together (15) . We have shown here by using the specific Cox-2 inhibitor NS-398 that Cox-2, which is also induced by prestimulation of macrophages with lipophilic cAMP analogs, is not responsible for cAMP-mediated protection against apoptosis. Expression of Cox-2 in macrophages is associated with prostaglandin E2 formation, which in turn may increase intracellular cAMP (41, 42) .
Deactivation of several macrophage responses by cAMP-elevating manipulations, such as adenyly cyclase stimulation, phosphodiesterase inhibition, and/or Cox-2 activation, is known and considered a standard regime for suppressing an early phase of the innate immune response known to be linked to macrophage stimulation (43, 44) . The action of cAMP-elevating agents in suppressing apoptosis is known for several other systems, i.e., for hepatocytes, neutrophils, or natural killer cell-derived cytotoxicity (45) (46) (47) . However, the mechanism of cAMP-mediated signal transduction in conferring resistance is largely unknown. Under inflammatory conditions, increased levels of cAMP-elevating prostaglandins acting via adenylyl cyclase may efficiently balance apoptotic initiating and counteracting pathways in cells of the monocyte/macrophage lineage. Our assumption that cAMP is involved in establishing cellular resistance was confirmed by applying lipophilic cAMP analogs that blocked all apoptotic features. Protection from apoptosis was not restricted to cultured murine RAW 264.7 macrophages but also occured in primary human monoctye-derived macrophages. Cellular responses against cAMP are mediated by activation of cAMP-dependent protein kinases (48) . The inactive kinase holoenzyme dissociates after the binding of cAMP and liberates the catalytic subunit, which in turn phosphorylates multiple substrates. Phosphorylation may affect structural components or enzyme activities, or alternatively, may promote alterations in gene transcription by phosphorylation and activation of the transcription factor CREB (49, 50) . Phosphorylated CREB binds to the promoter region of various genes and initiates transcription (51, 52) . Protection by cAMP-elicited signal transduction has been shown for human cancer cell growth (53, 54) , radiation resistance of melanoma cells (55) , and FAS-mediated apoptosis of primary hepatocytes (46) , although in some other systems, cAMP has been reported to act in a pro-apoptotic manner (56, 57) . Our study verifies the protective mechanism of conveying resistance against NO donors by lipophilic cAMP analog pretreatment. The successful use of decoy oligonucleotides with their ability to scavenge activated CREB, thereby abrogating protection and reestablishing p53 accumulation, confirmed the assumption of cAMP-derived gene induction. Although cAMP-responsive gene products remain elusive, they seem to participate in the regulation of p53, thereby affecting a rather upstream signaling component during NO-initiated apoptosis. An understanding of transducing mechanisms that confer inducible resistance against high doses of NO in immune-competent cells such as macrophages by cAMP-mediated gene activation may open avenues for pharmacologic intervention.
